DNA hydrogels for glioblastoma: programmable, tumor-responsive nanocarriers for precision therapy and theranostics

Abstract Glioblastoma (GBM) is the most lethal primary brain tumor, with median survival of only 12–18 months despite maximal surgery, radiotherapy, and chemotherapy. Its infiltrative growth, molecular heterogeneity, and therapy resistance, compounded by the restrictive blood–brain barrier (BBB), se...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Pooyan Alizadeh, Negin Yousefi Chermehini, Aida Baharampour, Pedram Ghanavati, Armin Jahangiri Babadi
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMC 2025-12-01
Serie:	Cancer Nanotechnology
Soggetti:	Glioblastoma DNA hydrogels Nanomedicine Blood–brain barrier Targeted drug delivery Stimuli-responsive therapy
Accesso online:	https://doi.org/10.1186/s12645-025-00352-z
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!